GLP-1 Education · 039
FLOW and Kidney Care: Connecting Evidence to a Clinical Monitoring Plan
Use kidney outcomes evidence alongside an accurate baseline and coordinated longitudinal care.
Dr. Sherry-Ann Brown, MD, PhD, FACC, FAHA
State the evidence anchor
FLOW studied semaglutide in people with type 2 diabetes and chronic kidney disease and found a reduction in its primary kidney and cardiovascular death composite. Interpretation requires the original eligibility and endpoint definitions. The following practice framework is an original synthesis for patient centered implementation.
Establish the kidney care context
Review the patient's kidney diagnosis, available eGFR and albuminuria information, relevant dates, diabetes history, and current medications. Clarify which clinician oversees kidney care and whether a nephrology plan is already in place. Evaluate the exact product's current indication and prescribing information. A single laboratory value provides limited context when earlier results, acute illness, and recent medication changes are important. Organizing the trajectory before prescribing helps the clinician understand the patient's clinical match to the evidence and the questions the next review must answer.
Coordinate treatment and monitoring
Discuss the proposed medicine with the patient in the context of the established kidney and diabetes plan. Select monitoring intervals and laboratory studies according to the clinical condition and accompanying treatment. Provide instructions for symptom changes that need earlier assessment. Confirm how results will be reviewed and how the patient will receive the decision. If several professionals prescribe medicines, identify who authorizes changes and ensure communication is concise. A coordinated plan makes it easier to interpret new findings and prevents the patient from receiving inconsistent directions from different services.
Explain outcomes without overpromising
Describe the studied composite and why its components matter. When quoting numerical results, use the original publication and state the followup period. Discuss uncertainty about the individual's future course. Record the evidence considered, clinical assessment, treatment choice, patient preferences, and practical followup actions. At later visits, revisit both treatment feasibility and the wider kidney care plan. The objective is a durable clinical process in which research informs decisions, each monitoring result receives attention, and the patient understands how the team will respond to change.
Check the kidney eligibility carefully
FLOW eligibility used both eGFR and albuminuria thresholds. A patient with a kidney diagnosis can still differ materially from the studied population. Review the original thresholds against dated clinical results before discussing direct applicability. The practical question is how closely the patient’s condition resembles the research setting and how current labeling and comprehensive kidney care inform the proposed decision.
Apply the framework
A patient with diabetes and albuminuric kidney disease asks about semaglutide after reading a headline. Gather their longitudinal kidney information, check the clinical match to FLOW and current labeling, and coordinate with their existing kidney team. Agree on the treatment decision and specify who will review the next laboratory results and contact the patient.